



STATISTICAL MODELING TO ASSESS VARIATION BETWEEN TESTS IN SINGLE ANTIGEN BEAD ANALYSIS

- The study shows proof of concept that statistical modeling can be employed to facilitate auto-reporting of SAB I/II data.
- Analysis of the distribution of the top 20 bead MFI's in a new test result compared to two prior results can be used to auto-result negative tests.

Hypothesis: We hypothesize statistical modeling can be employed to determine the result of a new single antigen bead test in comparison to two prior tests. The results of new tests can be auto-resulted if statistical modeling identifies no change in bead strength and specificity as compared to historic results.

Methods: For this quality improvement project, a data set of SAB I/II (n=280; One Lambda, Class I lot 15, Class II Lot 16) were analyzed to determine the percentage of negative tests, and frequency/characteristics of spuriously reactive beads defined as up to 2 positive beads >1000 MFI in the absence of CREG or broad group reactivity, and considered false positive. Data are acquired from sera batched in a 96-well plate, with Fusion acquisition software, and data analysis is performed in Histotrac. A second set of SAB I/II data was selected for negative (n=9 class I/II) or ‘spurious’ (n=21 class I/II) reactivity. Statistical models were used to assess whether the variation in distribution of bead strength and specificity in a new result were significantly different (outside 1 or 2 standard deviations; SD) from the two prior results.

Results and Figures:

Figure 1. A large proportion of SAB test results are reported negative after review. SAB results are negative in 51% and 55% of class I or II tests, respectively (positive threshold, 1000 MFI). An additional 24% of class I and 16% of class II are false positive due to spurious reactivity, and reported negative after expert review.






Figure 3. Examples of test results with spurious reactivity. Example histograms are from Patient 2 shown in Table 1.



Harry Pickering¹, Elaine F. Reed¹, Michelle J. Hickey¹

¹UCLA Immunogenetics Center, Department of Pathology & Laboratory Medicine
David Geffen School of Medicine at Los Angeles, CA, USA